USD
$0.00
(0.00%
)At Close (As of Oct 22, 2025)
$2.70M
Market Cap
-
P/E Ratio
-255.68
EPS
$210.00
52 Week High
$2.50
52 Week Low
HEALTHCARE
Sector
| Field | Value (None) |
|---|---|
| Gross Profit | $6.1M |
| Total Revenue | $23M |
| Cost Of Revenue | $17M |
| Costof Goods And Services Sold | $17M |
| Operating Income | -$8M |
| Selling General And Administrative | $3.2M |
| Research And Development | $3M |
| Operating Expenses | $14M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | $278K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $486K |
| Income Before Tax | -$8.1M |
| Income Tax Expense | $607K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | - |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$7.8M |
| Ebitda | -$7.4M |
| Net Income | -$8.7M |
| Field | Value (None) |
|---|---|
| Total Assets | $68M |
| Total Current Assets | $52M |
| Cash And Cash Equivalents At Carrying Value | $29M |
| Cash And Short Term Investments | $29M |
| Inventory | $1.7M |
| Current Net Receivables | $18M |
| Total Non Current Assets | $16M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $263K |
| Intangible Assets Excluding Goodwill | $263K |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $2.5M |
| Other Non Current Assets | - |
| Total Liabilities | $22M |
| Total Current Liabilities | $20M |
| Current Accounts Payable | $4.9M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $5.9M |
| Total Non Current Liabilities | $2.1M |
| Capital Lease Obligations | - |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $8M |
| Other Current Liabilities | $8.5M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $46M |
| Treasury Stock | - |
| Retained Earnings | -$10M |
| Common Stock | $482K |
| Common Stock Shares Outstanding | $6.1K |
| Field | Value (None) |
|---|---|
| Operating Cashflow | -$9.5M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $486K |
| Capital Expenditures | $363K |
| Change In Receivables | - |
| Change In Inventory | $1.6M |
| Profit Loss | - |
| Cashflow From Investment | -$361K |
| Cashflow From Financing | $34M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$8.7M |
| Field | Value (None) |
|---|---|
| Gross Profit | $6.1M |
| Total Revenue | $23M |
| Cost Of Revenue | $17M |
| Costof Goods And Services Sold | $17M |
| Operating Income | -$8M |
| Selling General And Administrative | $3.2M |
| Research And Development | $3M |
| Operating Expenses | $14M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | $278K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $486K |
| Income Before Tax | -$8.1M |
| Income Tax Expense | $607K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | - |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$7.8M |
| Ebitda | -$7.4M |
| Net Income | -$8.7M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Universe Pharmaceuticals Inc. (UPC) is a prominent player in the pharmaceutical sector, specializing in the development, marketing, and distribution of traditional Chinese medicine products in China. The company adeptly merges time-honored herbal practices with contemporary pharmaceutical techniques, catering to a diverse range of health needs. Positioned strategically to leverage the increasing consumer demand for alternative therapies, UPC benefits from an extensive distribution network and a steadfast commitment to quality. With a solid pipeline of innovative products and a focus on expanding its market presence, Universe Pharmaceuticals is well-equipped to drive substantial growth in the burgeoning health and wellness industry.